Naperville, IL -- (ReleaseWire) -- 05/13/2014 -- Reportstack, provider of premium market research reports announces the addition of Safinamide (Parkinsons Disease) - Forecast and Market Analysis to 2022 market report to its offering
Safinamide (Parkinsons Disease) - Forecast and Market Analysis to 2022
Parkinsons disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinsons disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. The publisher expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.
In 2012, Newron completed Phase III clinical trials for safinamide, a dual-mechanism a-aminoamide derivative, acting as an MAO-B and glutamate release inhibitor (EPDA, press release, May 14, 2012). In 2006, Merck Serono (a division of Merck KGaA) had acquired the exclusive worldwide rights for safinamide; however, in 2011 the deal was terminated, seeing Merck returning the compound to Newron due to concerns over the potential market size for the drug.
- Overview of Parkinsons disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape._x000D_
- Detailed information on Safinamide including product description, safety and efficacy profiles as well as a SWOT analysis._x000D_
- Sales forecast for Safinamide for the top seven countries from 2012 to 2022._x000D_
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Brazil.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return_x000D_
- Stay ahead of the competition by understanding the changing competitive landscape for Parkinsons disease_x000D_
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential_x000D_
- Make more informed business decisions from insightful and in-depth analysis of Safinamide performance _x000D_
- Obtain sales forecast for Safinamide from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Brazil).
To view the table of contents for this market research report please visit